BLASINGLE-USEVIALPriority Review
Approved
Feb 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KADCYLA is an antibody-drug conjugate (ADC) combining trastuzumab with emtansine, designed to treat HER2-positive breast cancer and other solid tumors. It works by targeting HER2-expressing cancer cells and delivering cytotoxic payload directly to tumor tissue, combining the specificity of monoclonal antibody therapy with potent chemotherapy. The mechanism enables improved efficacy with potentially better tolerability compared to conventional chemotherapy.
$4MPart D
PeakKADCYLA remains in peak commercial phase with modest Part D penetration, suggesting stable but limited primary-care adoption; the product maintains core oncology teams within Roche's specialized cancer unit.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Started May 2023
30 enrolled
Metastatic Solid TumorBrain Metastases
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Started Oct 2019
466 enrolled
HER2-positive Breast Cancer
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)
Started Jun 2018
32 enrolled
Advanced Breast Cancer
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Started Feb 2016
131 enrolled
Solid Tumor CancersLung CancerBladder Cancer+1 more
An Observational Study of Kadcyla Safety in Breast Cancer
Started May 2015
563 enrolled
Breast Cancer
Worked on KADCYLA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.